Cargando…
Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience
BACKGROUND: Advanced gastric cancer (GC) with liver metastasis is often characterized by multiple and bilobular metastases and may also be associated with extrahepatic metastatic lesions. Hence, many physicians consider that radical surgeries are contraindicated for liver metastases from GC (LMGC)....
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667407/ https://www.ncbi.nlm.nih.gov/pubmed/33251035 http://dx.doi.org/10.4292/wjgpt.v11.i5.110 |
_version_ | 1783610306573893632 |
---|---|
author | Yazawa, Takefumi Hori, Tomohide Yamamoto, Hidekazu Harada, Hideki Yamamoto, Michihiro Yamada, Masahiro Tani, Masaki Sato, Asahi Kamada, Yasuyuki Tani, Ryotaro Aoyama, Ryuhei Sasaki, Yudai Zaima, Masazumi |
author_facet | Yazawa, Takefumi Hori, Tomohide Yamamoto, Hidekazu Harada, Hideki Yamamoto, Michihiro Yamada, Masahiro Tani, Masaki Sato, Asahi Kamada, Yasuyuki Tani, Ryotaro Aoyama, Ryuhei Sasaki, Yudai Zaima, Masazumi |
author_sort | Yazawa, Takefumi |
collection | PubMed |
description | BACKGROUND: Advanced gastric cancer (GC) with liver metastasis is often characterized by multiple and bilobular metastases and may also be associated with extrahepatic metastatic lesions. Hence, many physicians consider that radical surgeries are contraindicated for liver metastases from GC (LMGC). According to the 2017 Japanese treatment guideline for GC, a smaller number of liver metastases without unresectable factors may be an indication for liver resection (LR) with curability. The actual 5-year overall survival (OS) rate ranges from 0 to 0.37. AIM: To present the institutional indications for LR for LMGC and identify important factors for prognostic outcomes. METHODS: In total, 30 patients underwent LR for LMGC during a 14-year period, and we evaluated the clinical, surgical, and oncological findings. In all patients, radical surgery with intentional lymphadenectomy was performed for the primary GC. The median follow-up duration after the initial LR was 33.7 mo, and three patients with no recurrence died of causes unrelated to the LMGC. The OS and recurrence-free survival rates after the initial LR were assessed. RESULTS: Seventeen patients had metachronous LMGC. The initial LR achieved curability in 29 patients. Perioperative chemotherapy was introduced in 23 patients. The median greatest LMGC dimension was 30 mm, and the median number of LMGC was two. Twenty-two patients had unilobular LMGC. The 5-year OS and recurrence-free survival rates were 0.48 and 0.28, respectively. The median survival duration and recurrence-free duration after the initial LR were 16.8 and 8.6 mo, respectively. Twenty-one patients developed recurrence after the initial LR. Additional surgeries for recurrence were performed in nine patients, and these surgeries clearly prolonged the patients’ survival. Pathological serosal invasion was an independent predictor of a poor prognostic outcome after the initial LR. Aggressive LR may be indicated for carefully selected patients with LMGC. CONCLUSION: Our results of LR for LMGC seem acceptable. Additional surgeries for recurrence after the initial LR might prolong OS. Pathological serosal invasion is important for poor prognostic outcomes. |
format | Online Article Text |
id | pubmed-7667407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-76674072020-11-27 Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience Yazawa, Takefumi Hori, Tomohide Yamamoto, Hidekazu Harada, Hideki Yamamoto, Michihiro Yamada, Masahiro Tani, Masaki Sato, Asahi Kamada, Yasuyuki Tani, Ryotaro Aoyama, Ryuhei Sasaki, Yudai Zaima, Masazumi World J Gastrointest Pharmacol Ther Retrospective Study BACKGROUND: Advanced gastric cancer (GC) with liver metastasis is often characterized by multiple and bilobular metastases and may also be associated with extrahepatic metastatic lesions. Hence, many physicians consider that radical surgeries are contraindicated for liver metastases from GC (LMGC). According to the 2017 Japanese treatment guideline for GC, a smaller number of liver metastases without unresectable factors may be an indication for liver resection (LR) with curability. The actual 5-year overall survival (OS) rate ranges from 0 to 0.37. AIM: To present the institutional indications for LR for LMGC and identify important factors for prognostic outcomes. METHODS: In total, 30 patients underwent LR for LMGC during a 14-year period, and we evaluated the clinical, surgical, and oncological findings. In all patients, radical surgery with intentional lymphadenectomy was performed for the primary GC. The median follow-up duration after the initial LR was 33.7 mo, and three patients with no recurrence died of causes unrelated to the LMGC. The OS and recurrence-free survival rates after the initial LR were assessed. RESULTS: Seventeen patients had metachronous LMGC. The initial LR achieved curability in 29 patients. Perioperative chemotherapy was introduced in 23 patients. The median greatest LMGC dimension was 30 mm, and the median number of LMGC was two. Twenty-two patients had unilobular LMGC. The 5-year OS and recurrence-free survival rates were 0.48 and 0.28, respectively. The median survival duration and recurrence-free duration after the initial LR were 16.8 and 8.6 mo, respectively. Twenty-one patients developed recurrence after the initial LR. Additional surgeries for recurrence were performed in nine patients, and these surgeries clearly prolonged the patients’ survival. Pathological serosal invasion was an independent predictor of a poor prognostic outcome after the initial LR. Aggressive LR may be indicated for carefully selected patients with LMGC. CONCLUSION: Our results of LR for LMGC seem acceptable. Additional surgeries for recurrence after the initial LR might prolong OS. Pathological serosal invasion is important for poor prognostic outcomes. Baishideng Publishing Group Inc 2020-11-08 2020-11-08 /pmc/articles/PMC7667407/ /pubmed/33251035 http://dx.doi.org/10.4292/wjgpt.v11.i5.110 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Retrospective Study Yazawa, Takefumi Hori, Tomohide Yamamoto, Hidekazu Harada, Hideki Yamamoto, Michihiro Yamada, Masahiro Tani, Masaki Sato, Asahi Kamada, Yasuyuki Tani, Ryotaro Aoyama, Ryuhei Sasaki, Yudai Zaima, Masazumi Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience |
title | Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience |
title_full | Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience |
title_fullStr | Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience |
title_full_unstemmed | Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience |
title_short | Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience |
title_sort | do liver metastases from gastric cancer contraindicate aggressive surgical resection? a 14-year single-center experience |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667407/ https://www.ncbi.nlm.nih.gov/pubmed/33251035 http://dx.doi.org/10.4292/wjgpt.v11.i5.110 |
work_keys_str_mv | AT yazawatakefumi dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT horitomohide dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT yamamotohidekazu dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT haradahideki dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT yamamotomichihiro dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT yamadamasahiro dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT tanimasaki dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT satoasahi dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT kamadayasuyuki dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT taniryotaro dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT aoyamaryuhei dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT sasakiyudai dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience AT zaimamasazumi dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience |